Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Evaluation of outcomes in converting from intravenous ondansetron to oral granisetron: an observational study
Autore:
McCune, JS; Oertel, MD; Pfeifer, D; Houston, SA; Bingham, A; Sawyer, WT; Lindley, CM;
Indirizzi:
Univ N Carolina, Sch Pharm, Chapel Hill, NC 27599 USA Univ N Carolina Chapel Hill NC USA 27599 Pharm, Chapel Hill, NC 27599 USA Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA Univ N Carolina Chapel Hill NC USA 27599 h Med, Chapel Hill, NC 27599 USA Univ Washington, Sch Pharm, Seattle, WA 98195 USA Univ Washington SeattleWA USA 98195 on, Sch Pharm, Seattle, WA 98195 USA Univ N Carolina Hosp, Chapel Hill, NC USA Univ N Carolina Hosp Chapel Hill NC USA rolina Hosp, Chapel Hill, NC USA Quintiles Cardiovasc Therapeut, Drug Dev Serv, Res Triangle Pk, NC USA Quintiles Cardiovasc Therapeut Res Triangle Pk NC USA riangle Pk, NC USA
Titolo Testata:
ANNALS OF PHARMACOTHERAPY
fascicolo: 1, volume: 35, anno: 2001,
pagine: 14 - 20
SICI:
1060-0280(200101)35:1<14:EOOICF>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHEMOTHERAPY-INDUCED NAUSEA; CISPLATIN-INDUCED EMESIS; DOUBLE-BLIND; PLUS DEXAMETHASONE; PARALLEL-GROUP; PROPHYLAXIS; MULTICENTER; PREVENTION; ANTIEMETICS; GUIDELINES;
Keywords:
antiemetic guidelines; chemotherapy; granisetron; ondansetron;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Lindley, CM Univ N Carolina, Sch Pharm, CB 7360,Beard Hall, Chapel Hill, NC 27599 USA Univ N Carolina CB 7360,Beard Hall Chapel Hill NC USA 27599 SA
Citazione:
J.S. McCune et al., "Evaluation of outcomes in converting from intravenous ondansetron to oral granisetron: an observational study", ANN PHARMAC, 35(1), 2001, pp. 14-20

Abstract

OBJECTIVE: TO describe a systematic evaluation of the outcomes associated with revising institutional guidelines for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) to promote cost-effective use of the serotonin (5-HT3) antagonists. METHODS: The 5-HT3 antagonist of choice in the antiemetic guidelines was revised from intravenous ondansetron to oral granisetron in August 1995. Patient assessments were conducted immediately prior to (Period 1) and after (Period 2) guideline revision using validated questionnaires. The effectiveness of the two 5-HT3 antagonists were compared and reported to the prescribing oncologists. Outcomes were assessed one year after guideline revision (Period 3) using identical methods. 1RESULTS: No difference was found in the rate of total control (no emesis, no nausea) between patients receiving oral granisetron (60%) and intravenous ondansetron (56%) (p = 0.408, Period 1 vs. 2). Nausea severity, the number of emesis episodes, and use of rescue antiemetics were also equivalent. Prescriber compliance with using the 5-HT3 antagonist of choice and dose increased from 48% to 61% following adoption of oral granisetron. By Period 3,compliance increased to 78%, and satisfactory control of acute CINV was again documented. The costs for prevention of acute CINV decreased from $107 in Period 1 (intravenous ondansetron only) to $65 in Period 3 (oral granisetron). CONCLUSIONS: Outcomes associated with use of oral granisetron and intravenous ondansetron were equivalent in this patient population. Guideline revision and outcome documentation by the oncology pharmacists resulted in increased compliance with institution guidelines and a 40% cost savings.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/07/20 alle ore 15:06:24